Astellas Antifungal Nabs 12-Year Exclusivity: QIDP+Orphan Combos Are Rare

Cresemba (isavuconazonium), the first antifungal approved with added exclusivity award for Qualified Infectious Disease Products, also becomes first product to receive both QIDP and Orphan Drug exclusivity.

More from United States

More from North America